Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Genmab A/S Dkk (GNMSF)

Genmab A/S Dkk (GNMSF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 11,039,770
  • Shares Outstanding, K 61,281
  • Annual Sales, $ 359,310 K
  • Annual Income, $ 167,630 K
  • 60-Month Beta 0.11
  • Price/Sales 135.29
  • Price/Cash Flow 66.03
  • Price/Book 10.09
  • Price/Earnings ttm 56.35
  • Earnings Per Share ttm 0.68
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 06/25/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 0.31
  • Number of Estimates 2
  • High Estimate 0.57
  • Low Estimate 0.06
  • Prior Year 0.54
  • Growth Rate Est. (year over year) -42.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
168.7500 +6.76%
on 06/04/19
185.0500 -2.65%
on 06/12/19
+1.0205 (+0.57%)
since 05/21/19
3-Month
160.8000 +12.03%
on 05/13/19
185.0500 -2.65%
on 06/12/19
+3.1500 (+1.78%)
since 03/21/19
52-Week
119.1000 +51.26%
on 10/25/18
185.0500 -2.65%
on 06/12/19
+32.1500 (+21.72%)
since 06/21/18

Most Recent Stories

More News
Why Earnings Season Could Be Great for Genmab (GNMSF)

Genmab (GNMSF) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

GNMSF : 180.1500 (-0.41%)
Global Blood (GBT) Reports Narrower-Than-Expected Loss in Q1

Global Blood (GBT) reports narrower-than-expected loss in the first quarter of 2019.

GNMSF : 180.1500 (-0.41%)
GBT : 63.46 (+0.73%)
GILD : 68.75 (-0.91%)
FCSC : 1.95 (-2.01%)
Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss

Agenus' (AGEN) earnings beat estimates in the first quarter of 2019. Sales marginally miss the same.

AGEN : 3.02 (+0.67%)
GNMSF : 180.1500 (-0.41%)
GILD : 68.75 (-0.91%)
FCSC : 1.95 (-2.01%)
Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates

Horizon Therapeutics' (HZNP) sales beat estimates in the first quarter of 2019, primarily owing to strong performance of Krystexxa, Ravicti, Procysbi and Rayos.

GNMSF : 180.1500 (-0.41%)
HZNP : 23.45 (-1.35%)
GILD : 68.75 (-0.91%)
FCSC : 1.95 (-2.01%)
Amicus' (FOLD) Earnings & Revenues Miss Estimates in Q1

Amicus (FOLD) reports wider-than-expected loss in the first quarter of 2019. Also, sales miss estimates.

FOLD : 11.99 (-3.23%)
GNMSF : 180.1500 (-0.41%)
GILD : 68.75 (-0.91%)
FCSC : 1.95 (-2.01%)
AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates

AMAG (AMAG) reports wider-than-expected loss and misses sales estimates in the first quarter of 2019.

LGND : 109.89 (-1.79%)
GNMSF : 180.1500 (-0.41%)
AMAG : 8.44 (-5.91%)
FCSC : 1.95 (-2.01%)
What's in the Cards for AcelRx (ACRX) This Earnings Season?

We expect AcelRx (ACRX) to provide update on the launch of its newly approved drug DSUVIA, when it reports first-quarter 2019 results.

GNMSF : 180.1500 (-0.41%)
HZNP : 23.45 (-1.35%)
ACRX : 2.29 (-2.55%)
INO : 2.42 (-7.63%)
What's in Cards for Cumberland (CPIX) This Earnings Season?

Cumberland (CPIX) will provide updates on pipeline candidates with the release of its first-quarter 2019 results.

CPIX : 6.48 (+2.86%)
GNMSF : 180.1500 (-0.41%)
HZNP : 23.45 (-1.35%)
INO : 2.42 (-7.63%)
What's in the Cards for Corbus (CRBP) This Earnings Season?

Corbus (CRBP) will provide updates on its lead candidate lenabasum, when it releases first-quarter 2019 results.

CRBP : 7.10 (-3.40%)
GNMSF : 180.1500 (-0.41%)
HZNP : 23.45 (-1.35%)
INO : 2.42 (-7.63%)
Seattle Genetics' Adcetris Progresses Well Amid Competition

Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.

GNMSF : 180.1500 (-0.41%)
MRK : 85.66 (+1.29%)
SGEN : 70.68 (-1.48%)
BMY : 45.65 (-7.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade GNMSF with:

Key Turning Points

2nd Resistance Point 180.2033
1st Resistance Point 180.1767
Last Price 180.1500
1st Support Level 180.1367
2nd Support Level 180.1233

See More

52-Week High 185.0500
Last Price 180.1500
Fibonacci 61.8% 159.8571
Fibonacci 50% 152.0750
Fibonacci 38.2% 144.2929
52-Week Low 119.1000

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar